Drug Profile

Norovirus vaccine - Vaxart

Latest Information Update: 01 Sep 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Vaxart
Class Synthetic vaccines; Viral vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Phase I Norovirus infections

Most Recent Events

26 Aug 2026 Vaxart has patent protection for Norovirus vaccine technology across 13 major European jurisdictions, including Germany, France, Italy, Spain, and the United Kingdom
23 Jan 2026 Norovirus vaccine - Vaxart is available for licensing as of 15 Jan 2026. http://www.vaxart.com
10 Sep 2025 Immunogenicity data from a phase I trial in Norovirus infections released by Vaxart

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com